Document is current
Any future updates will be listed below
-
Authors
Mikkelsen, Kristian H.
Vilsbøll, Tina
Holst, Jens J.
Hartmann, Bolette
Knop, Filip K.
Frost, Morten https://orcid.org/0000-0002-5608-1589
-
Funding
Funding for this research was provided by:
Strategiske Forskningsråd (133-00283)
- License Information
-
More Information
Article History
Received: 28 February 2018
Accepted: 29 August 2018
First Online: 4 September 2018
Ethics approval and consent to participate
: The study was approved by the Scientific-Ethics Committee of the Capital Region of Denmark, registered with ClinicalTrials.gov (ID: NCT01633762) and conducted according to the Helsinki Declaration. Written informed consent was obtained from all study participants.
: Nothing relating to an individual person was included in this publication.
: K.H.M. holds stocks in Chr. Hansen. F.K.K. has received personal honoraria for consulting, lectures and/or advisory board participation within the last 36 months from Amgen, AstraZeneca, Eli Lilly, Merck/MSD, Novo Nordisk, Sanofi and Zealand Pharma, and has received unrestricted research grants from AstraZeneca and Sanofi. T.V, M.F, JJH and BH declare no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
